JP2006525796A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525796A5
JP2006525796A5 JP2006502644A JP2006502644A JP2006525796A5 JP 2006525796 A5 JP2006525796 A5 JP 2006525796A5 JP 2006502644 A JP2006502644 A JP 2006502644A JP 2006502644 A JP2006502644 A JP 2006502644A JP 2006525796 A5 JP2006525796 A5 JP 2006525796A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
polynucleotide sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006502644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2004/000182 external-priority patent/WO2004076621A2/en
Publication of JP2006525796A publication Critical patent/JP2006525796A/ja
Publication of JP2006525796A5 publication Critical patent/JP2006525796A5/ja
Pending legal-status Critical Current

Links

JP2006502644A 2003-02-27 2004-02-24 インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物 Pending JP2006525796A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44986303P 2003-02-27 2003-02-27
PCT/IL2004/000182 WO2004076621A2 (en) 2003-02-27 2004-02-24 Compositions of nucleic acids for treating and detecting influenza virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010180666A Division JP2010279385A (ja) 2003-02-27 2010-08-12 インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物

Publications (2)

Publication Number Publication Date
JP2006525796A JP2006525796A (ja) 2006-11-16
JP2006525796A5 true JP2006525796A5 (enExample) 2007-02-01

Family

ID=32927582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006502644A Pending JP2006525796A (ja) 2003-02-27 2004-02-24 インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物
JP2010180666A Pending JP2010279385A (ja) 2003-02-27 2010-08-12 インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010180666A Pending JP2010279385A (ja) 2003-02-27 2010-08-12 インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物

Country Status (7)

Country Link
US (3) US7786279B2 (enExample)
EP (1) EP1597350B1 (enExample)
JP (2) JP2006525796A (enExample)
KR (1) KR101130181B1 (enExample)
AU (1) AU2004215133B2 (enExample)
CA (1) CA2517074A1 (enExample)
WO (1) WO2004076621A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1597350B1 (en) * 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection
US7494776B2 (en) 2005-07-07 2009-02-24 Beckman Coulter, Inc. Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands
US9862770B2 (en) * 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
EP1843158A1 (de) * 2006-04-05 2007-10-10 Micronas Holding GmbH Nachweissystem für Krankheitserreger
KR101775929B1 (ko) * 2007-01-19 2017-09-07 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
GB0702183D0 (en) * 2007-02-05 2007-03-14 Iti Scotland Ltd Pathogen binding
JP5579449B2 (ja) 2008-02-01 2014-08-27 株式会社プロテクティア 膜融合阻害剤
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
KR101034490B1 (ko) 2009-06-23 2011-05-17 한밭대학교 산학협력단 생체 안전성이 뛰어난 인플루엔자 바이러스 백신용 항원성 에피토프로서의 재조합 헤마글루티닌 단백질
WO2010150982A2 (ko) * 2009-06-23 2010-12-29 한밭대학교 산학협력단 안전성이 뛰어난 인플루엔자 바이러스 백신용 재조합 헤마글루티닌 단백질 및 이를 함유하는 생분해성 ｐｌｇａ 미립자의 제조 방법
CN102480952B (zh) 2009-07-31 2015-01-21 国立大学法人大阪大学 抗菌剂
US10584181B2 (en) * 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
JP5996837B2 (ja) * 2010-05-28 2016-09-21 小林製薬株式会社 インフルエンザウイルスの感染抑制剤
JP5717127B2 (ja) * 2010-11-15 2015-05-13 独立行政法人産業技術総合研究所 新型インフルエンザウイルスのヘマグルチニンに結合するアプタマー
US20130064811A1 (en) * 2011-09-09 2013-03-14 International Business Machines Corporation Methods to Enhance Cancer Treatment
RU2620068C2 (ru) 2011-11-23 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные по отношению к her3, и их применения
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2857514A4 (en) * 2012-06-04 2016-02-24 Nec Solution Innovators Ltd NUCLEIC ACID MOLECULE BINDING IN INFLUENZA VIRUS AND USE THEREOF
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
AU2014220705C1 (en) * 2013-02-22 2018-10-18 Wilex Ag CAIX stratification based cancer treatment
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
EP2784510A1 (en) * 2013-03-25 2014-10-01 Universität Zu Köln Methods of diagnosing and differentiating oncocytoma and malignant renal carcinoma as well as products and uses relating thereto
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
WO2015048008A2 (en) * 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9903871B2 (en) * 2014-07-15 2018-02-27 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from nucleoredoxin X1 and uses thereof
GB201419976D0 (en) * 2014-11-10 2014-12-24 Univ Newcastle Biomarkers for disease progression in melanoma
KR20170082537A (ko) * 2014-11-14 2017-07-14 제넨테크, 인크. Vegf 길항제에 대한 반응 예측
CN107108718B (zh) * 2014-12-08 2022-07-22 北京强新生物科技有限公司 可溶性通用的增强adcc的合成融合基因和融合肽的技术及其应用
JP2018516230A (ja) * 2015-03-18 2018-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティ カリウムチャネルｋｃｎｋ９を標的とする新規モノクローナル抗体阻害剤
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
KR101796277B1 (ko) * 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
CN112334481A (zh) * 2018-06-11 2021-02-05 葛兰素史克消费保健（美国）控股有限责任公司 用于快速乙型流感诊断测试的抗体对
KR20200060969A (ko) 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
LU101073B1 (en) * 2018-12-21 2020-06-24 Luxembourg Inst Science & Tech List Dna aptamers specific of adenovirus types
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
KR102393872B1 (ko) * 2019-08-28 2022-05-04 엠브릭스 주식회사 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections
CN113773401B (zh) * 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
KR100211552B1 (ko) 1990-08-03 1999-08-02 디. 꼬쉬 유전자 발현 억제용 화합물 및 방법
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
AU1435492A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
JPH08508491A (ja) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
WO1997003085A1 (en) * 1995-07-11 1997-01-30 Nexstar Pharmaceuticals, Inc. Intracellular action of nucleic acid ligands
EP1597350B1 (en) * 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Nucleic acid molecules, and compositions containing same useful for treating and detecting influenza virus infection

Similar Documents

Publication Publication Date Title
JP2006525796A5 (enExample)
CN102471300B (zh) 用于增强病毒效力的组合物和方法
JP2006523453A5 (enExample)
IL296483A (en) Oligonucleotides to reduce pd–l1 expression
WO2017143449A1 (en) Smc combination therapy for the treatment of cancer
JP2008056679A5 (enExample)
CA2526691A1 (en) High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
JP2010516290A5 (enExample)
JP6158833B2 (ja) ベータ−カテニン関連疾患を処置するための有機組成物
JP2010502207A5 (enExample)
JP2006512300A5 (enExample)
JPWO2021239880A5 (enExample)
JP2019514913A5 (enExample)
CN106029874B (zh) 浆细胞样树突状细胞的耗竭
JP2013517226A5 (ja) ウイルス、バクテリア、寄生生物に感染した細胞及び／又は腫瘍細胞に影響を及ぼす生物学的有効分子群、及び該分子群を適用するための方法
JPWO2021116462A5 (enExample)
CN113395975A (zh) 用于靶向血脑屏障的组合物和方法
JP2013504603A5 (enExample)
Dabrowska et al. Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2
EP4504946A2 (en) Vector for generating a circular rna
TW202221126A (zh) 用於鑑別及特徵化指環病毒之方法及其用途
US20170233760A1 (en) Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit
JP2008503569A5 (enExample)
JP2024526189A (ja) 予防および治療のためのｇ－四重鎖含有オリゴヌクレオチド
Aghamollaei et al. Emerging Technologies for the Treatment of COVID-19